---

ANOSMIA — A Comprehensive Account

As per Scott Brown's, Cummings (Otolaryngology HNS), Stell & Maran, Dhingra, Hazarika, Zakir Hussain & Recent Literature

---

1. DEFINITION & TERMINOLOGY

---

2. ANATOMY OF THE OLFACTORY SYSTEM

2.1 Peripheral Apparatus

• Superior third of the nasal septum
• Superior turbinate
• Roof of the nasal cavity (cribriform plate area)

2.2 The Olfactory Pathway — Step by Step

Odorant molecules (airborne, volatile, hydrophobic)
            ↓
  Dissolve in olfactory mucus (Bowman's gland secretion)
            ↓
  Bind to specific Olfactory Receptor Proteins (ORPs)
  on cilia of Olfactory Receptor Neurons (ORNs)
            ↓
  G-protein (Golf) activation → Adenylyl cyclase ↑
  → cAMP ↑ → Ca²⁺ channel opens → depolarization
            ↓
  Action potential in unmyelinated axons (CN I fila)
            ↓
  Cross cribriform plate of ethmoid bone (20–25 fila)
            ↓
  Synapse in OLFACTORY BULB (glomeruli)
  [1st relay — mitral & tufted cells]
            ↓
  Olfactory tract (medial & lateral olfactory striae)
            ↓
  PRIMARY OLFACTORY CORTEX
  • Piriform cortex (main)
  • Amygdala (emotional/fear response)
  • Entorhinal cortex (memory, hippocampal link)
  • Anterior olfactory nucleus
  • Olfactory tubercle
  • Periamygdaloid cortex
            ↓
  SECONDARY OLFACTORY AREAS
  • Orbitofrontal cortex (conscious perception, flavor)
  • Hypothalamus (autonomic, endocrine responses)
  • Hippocampus (olfactory memory — Proust effect)
  • Thalamus (mediodorsal nucleus) → prefrontal cortex

Key anatomical point: The olfactory nerve (CN I) is the only cranial nerve that projects directly to the cortex without a thalamic relay for primary processing.

---

2.3 Olfactory System Anatomy & Classification Diagram

---

3. EPIDEMIOLOGY

• General population prevalence: ~5% have significant olfactory impairment (hyposmia/anosmia)
• Age >65 years: ~25% affected (presbyosmia)
• Age >80 years: >60% affected
• Congenital anosmia: 1 in 10,000 births
• COVID-19 pandemic: anosmia reported in 15–96% of cases (varies by variant and measurement method)
• Men have slightly worse olfaction than women at comparable ages
• Smokers demonstrate significantly reduced olfactory performance

---

4. CLASSIFICATION OF ANOSMIA

4.1 By Site of Lesion (Cummings / Scott Brown)

ANOSMIA
├── TRANSPORT (CONDUCTIVE) ANOSMIA
│   └── Odorants cannot reach olfactory epithelium
│       • Nasal obstruction (polyps, deviated septum,
│         turbinate hypertrophy, foreign body)
│       • Nasal tumors (inverted papilloma, carcinoma)
│       • Allergic / CRS-related mucosal edema
│
├── SENSORINEURAL ANOSMIA
│   ├── PERIPHERAL (damage to ORN/epithelium)
│   │   • Post-viral (most common overall)
│   │   • Toxic/occupational (Cd, Pb, Hg, chlorine)
│   │   • Drug-induced
│   │   • Radiation-induced
│   │   • Idiopathic
│   │
│   └── CENTRAL (bulb, tract, cortical)
│       • Head trauma (shearing of olfactory fila)
│       • Neurodegenerative (Parkinson's, Alzheimer's)
│       • Tumors (olfactory groove meningioma,
│         frontal lobe, olfactory neuroblastoma)
│       • Psychiatric (schizophrenia)
│       • Epilepsy (uncinate fits — phantosmia)
│
└── CONGENITAL ANOSMIA
    • Kallmann syndrome
    • Isolated congenital anosmia (CNGA2 mutation)
    • Ciliary dyskinesia (Kartagener syndrome)

4.2 By Duration

---

5. ETIOLOGY IN DETAIL

5.1 Upper Respiratory Tract Infections (URTI) — Most Common

• Mechanism: Direct viral damage to ORN cilia and sustentacular cells; post-viral neuroinflammation; replacement of olfactory epithelium by respiratory epithelium
• Viruses: Rhinovirus, influenza, parainfluenza, adenovirus, SARS-CoV-2
• Prognosis: ~33% recover fully; ~33% partially; ~33% permanent
• Special — COVID-19: SARS-CoV-2 infects sustentacular and basal supporting cells (rich in ACE2/TMPRSS2 receptors) → secondary ORN damage; notably WITHOUT mucosal thickening or olfactory cleft disease on imaging (ICAR:RS 2021, p. 16)

5.2 Head Trauma

• Second most common cause in clinical practice (Harrison's, p. 1007)
• Mechanism: Shearing of olfactory fila at cribriform plate during acceleration-deceleration injury; cribriform plate fracture NOT required
• Occipital head injuries are more likely to cause anosmia than frontal impacts (contrecoup effect on olfactory bulb)
• Severity correlates with Glasgow Coma Scale score and duration of post-traumatic amnesia
• Bilateral anosmia is more common than unilateral

5.3 Chronic Rhinosinusitis (CRS)

• Mechanism: Mucosal edema obstructs olfactory cleft (transport loss) + secondary mucosal metaplasia (sensorineural component)
• CRS with nasal polyposis causes more severe and persistent hyposmia/anosmia
• Olfactory loss is a major diagnostic criterion for CRS (EPOS 2020, ICAR:RS 2021)
• Topical and systemic corticosteroids partially restore olfaction by reducing edema

5.4 Neurodegenerative Diseases

• Parkinson's disease: Anosmia/hyposmia precedes motor symptoms by 4–6 years in >90% of patients — a prodromal biomarker; Lewy bodies present in olfactory bulb early (Braak stage 1)
• Alzheimer's disease: Impaired odor identification; tau pathology in entorhinal cortex
• iRBD (idiopathic REM sleep behavior disorder): Same magnitude of smell loss as PD; may predict conversion to PD (Harrison's, p. 1009)
• Multiple system atrophy, Huntington's disease — less severe OD

5.5 Congenital — Kallmann Syndrome

• Failure of migration of GnRH neurons and olfactory neurons from olfactory placode
• Classic triad: Anosmia + hypogonadotropic hypogonadism + midline defects
• X-linked (KAL1 gene), autosomal dominant/recessive forms
• MRI: absent/hypoplastic olfactory bulbs and sulci

5.6 Toxins and Drugs

5.7 Endocrine Causes

• Hypothyroidism (reversible with thyroxine)
• Diabetes mellitus (peripheral neuropathy + mucosal changes)
• Adrenal insufficiency
• Pregnancy (temporary hyperosmia in first trimester, occasionally anosmia)

5.8 Nutritional Deficiencies

• Zinc deficiency — essential cofactor for olfactory receptor function; zinc supplementation restores OD in deficient patients
• Vitamin A deficiency — required for olfactory epithelium regeneration; retinoic acid regulates ORN differentiation
• Vitamin B12, iron deficiency

5.9 Tumors

• Olfactory groove meningioma — compresses olfactory bulb/tract; may cause Foster Kennedy syndrome (ipsilateral anosmia + optic atrophy, contralateral papilledema)
• Olfactory neuroblastoma (esthesioneuroblastoma) — arises from olfactory epithelium
• Frontal lobe tumors, craniopharyngioma

5.10 Psychiatric

• Schizophrenia — impaired odor identification (central processing)
• Major depression — reduced olfactory sensitivity
• Anorexia nervosa

---

6. PATHOPHYSIOLOGY

6.1 Peripheral Mechanism (Post-Viral / Toxic)

Viral/toxic insult to olfactory epithelium
            ↓
Damage to sustentacular cells
→ Loss of metabolic support for ORNs
            ↓
ORN degeneration (axon retraction, apoptosis)
            ↓
Inflammatory infiltrate in olfactory mucosa
→ IL-6, TNF-α, IFN-γ elevation
            ↓
Basal cell activation → attempted regeneration
            ↓
If insult mild: Re-epithelialization → recovery
If severe: Replacement by respiratory-type epithelium
→ Persistent anosmia

6.2 Central Mechanism (Head Trauma)

Deceleration injury / blast
            ↓
Shearing of olfactory fila (fascicles of CN I)
at cribriform plate
            ↓
Wallerian degeneration of proximal axons
→ Retrograde degeneration of olfactory bulb
            ↓
Glial scarring at cribriform plate level
→ Blocks any regenerating axons from ORNs
            ↓
Permanent anosmia (majority)
Partial recovery possible (up to 18 months)

6.3 Molecular Olfactory Transduction (Normal)

Odorant + Olfactory Receptor Protein (G-protein coupled)
            ↓
Golf (Gαs subtype) activation → adenylyl cyclase III ↑
            ↓
cAMP ↑ → CNG channel (cyclic nucleotide-gated) opens
            ↓
Na⁺ / Ca²⁺ influx → membrane depolarization
            ↓
Ca²⁺ activates Ca²⁺-gated Cl⁻ channels → amplification
            ↓
Action potential → olfactory fila → cribriform plate
            ↓
Olfactory bulb → glomeruli → mitral/tufted cells
            ↓
Centrifugal modulation (noradrenergic, cholinergic,
serotonergic, dopaminergic) from basal forebrain

---

7. CLINICAL FEATURES

7.1 History — Key Points (Dhingra; Hazarika)

• Onset: Sudden (post-viral, trauma) vs. insidious (CRS, neurodegenerative)
• Duration: Acute vs. chronic
• Unilateral vs. bilateral: Unilateral anosmia suggests structural/mass lesion; bilateral suggests diffuse mucosal/central cause
• Associated taste disturbance (flavor loss — most "taste" is retronasal olfaction)
• Nasal symptoms: Blockage, discharge, polyps, epistaxis
• Head injury history
• Drug history: Intranasal medications, ACE inhibitors
• Occupational exposure: Chemical industry, mining
• Neurological symptoms: Memory loss, Parkinsonism features
• COVID-19 history

7.2 Common Presentations

---

8. INVESTIGATION AND DIAGNOSIS

8.1 Clinical Examination

1. Anterior rhinoscopy / nasal endoscopy:
   • Olfactory cleft obstruction (polyps, deviated septum, mucosal edema)
   • Olfactory cleft — should be clear on nasal endoscopy
   • Olfactory neuroblastoma assessment
2. Neurological examination:
   • Cranial nerve assessment (particularly CN I, II, V)
   • Cognitive screening (MMSE for neurodegenerative)
   • Cerebellar and extrapyramidal signs

8.2 Olfactory Testing (Psychophysical)

8.3 Imaging

Olfactory bulb volume (OBV): MRI-measured OBV correlates with olfactory function — significantly reduced in post-viral anosmia, Kallmann syndrome, and neurodegenerative OD. (Cummings, 7th ed.)

8.4 Laboratory Tests

• Serum zinc level
• TFTs (hypothyroidism)
• Blood glucose / HbA1c
• B12, folate
• Autoimmune panel (Sjögren, SLE — rare cause)
• Genetic testing (Kallmann: KAL1, FGFR1, PROKR2)

---

9. DIAGNOSTIC FLOWCHART

Patient presents with SMELL LOSS
            │
            ▼
   Detailed History & Examination
   + Nasal Endoscopy + CN assessment
            │
     ┌──────┴──────┐
     │             │
  BILATERAL    UNILATERAL
     │             │
     │             ▼
     │    Structural cause likely
     │    → CT sinuses / MRI
     │    → Rule out tumor/mass
     │
     ▼
Nasal Endoscopy Findings?
     │
  ┌──┴──┐
  │     │
 YES    NO
(Obstruction/  (Clear olfactory cleft)
 polyps/CRS)         │
  │             ┌────┴────┐
  │             │         │
  │         ACUTE    CHRONIC
  │         (<12wk)  (>12wk)
  │             │         │
  │          Post-   MRI brain
  │          viral    olfactory
  │          URTI /   bulbs
  ▼          COVID  + psycho-
CONDUCTIVE         physical
ANOSMIA           testing
  │                  │
  ▼                  ▼
Treat CRS     Post-viral / Post-traumatic /
(steroids,    Neurodegenerative / Kallmann
 surgery)            │
                     ▼
           PSYCHOPHYSICAL TESTING
           (UPSIT / Sniffin' Sticks)
                     │
           ┌─────────┼─────────┐
           │         │         │
         Mild    Moderate    Severe/
        hyposmia hyposmia   Anosmia
           │         │         │
           └─────────┴────┬────┘
                          │
                 Further workup:
                 Zinc, TFTs, MRI,
                 OERPs if needed
                          │
                          ▼
              DIRECTED MANAGEMENT

---

10. MANAGEMENT

10.1 General Principles (Scott Brown; Cummings; Dhingra)

1. Treat the underlying cause wherever possible
2. Patient counseling — safety advice (gas leaks, fire, food spoilage detection impaired)
3. Dietary advice — flavor enhancement with texture and temperature

10.2 Specific Management by Etiology

A. Conductive Anosmia (CRS / Polyps)

• Medical:
  • Topical intranasal corticosteroids (fluticasone, mometasone, budesonide)
  • Short course systemic steroids (prednisolone 0.5 mg/kg for 5–7 days) — most effective for rapid improvement
  • Saline nasal irrigation (improves mucociliary clearance)
  • Antihistamines (if allergic rhinitis contributing)
  • Antibiotics for acute bacterial rhinosinusitis (ICAR:RS 2021, p. 6)
• Surgical:
  • Functional Endoscopic Sinus Surgery (FESS) — opens olfactory cleft, removes polyps
  • Septoplasty for septal deviation
  • Post-operative olfaction improves in ~70% with polyps (Scott Brown's, 8th ed.)

B. Post-Viral Anosmia

• Spontaneous recovery common in the first 3 months
• Olfactory training (OT) — evidence-based; considered first-line for post-viral and COVID-19 anosmia:
  • Daily bilateral exposure to 4 odors: rose, eucalyptus, lemon, clove (phenyl ethyl alcohol, cineole, citronellal, eugenol)
  • Minimum 12-week course; extended 24-week protocol more effective
  • Mechanism: stimulates neurogenesis, axonal sprouting, neuroplasticity
• Topical corticosteroids — limited evidence but used widely
• Vitamin A nasal drops — retinoic acid promotes olfactory neurogenesis; Vitamin A nasal drops (10,000 IU/mL) — studied by Hummel et al.
• Alpha-lipoic acid — antioxidant; some evidence for post-viral OD
• Oral prednisolone — controversial; short course may help if inflammatory etiology

C. Post-Traumatic Anosmia

• Conservative management; spontaneous recovery possible up to 18 months post-injury
• Olfactory training — same protocol as post-viral
• No surgical intervention useful for CN I shearing injuries
• Meningocele/encephalocele repair if CSF rhinorrhoea accompanies cribriform plate fracture

D. COVID-19 Anosmia

• First-line: Olfactory training (same protocol as above)
• Oral corticosteroids: Limited evidence; not routinely recommended
• Intranasal corticosteroid irrigation: Budesonide 0.5 mg in 240 mL saline — recommended by some centers
• Palmitoylethanolamide (PEA) + luteolin: Anti-inflammatory neuroprotective; emerging evidence
• Platelet-rich plasma (PRP) intranasal injections — early small trials, promising
• Majority recover within 4–8 weeks; ~10% have persistent OD >6 months (ICAR:RS 2021, p. 16)

E. Kallmann Syndrome

• Hormone replacement (GnRH therapy or sex steroids) addresses hypogonadism
• Anosmia itself is not treatable — permanent due to olfactory bulb aplasia
• Genetic counseling

F. Neurodegenerative OD (Parkinson's, Alzheimer's)

• No disease-specific treatment reverses OD
• Manage underlying disease
• OD may serve as a screening tool in PD — early detection programs

G. Nutritional Deficiency

• Zinc supplementation (220 mg zinc sulfate twice daily) — evidence-based for zinc-deficiency anosmia
• Vitamin A — oral + topical nasal drops for deficiency states

H. Drug-Induced

• Discontinue offending drug if possible; most cases reversible

---

11. MANAGEMENT FLOWCHART

CONFIRMED ANOSMIA / HYPOSMIA
            │
            ▼
   Identify Etiology
            │
   ┌────────┼────────┬─────────┬──────────┐
   │        │        │         │          │
CONDUCTIVE POST-  POST-    NEURODE-  CONGENITAL/
(CRS/      VIRAL  TRAUMATIC GENERATIVE KALLMANN
polyps)    │        │         │          │
   │        │        │         │          │
   ▼        ▼        ▼         ▼          ▼
Topical   Olfactory Olfactory Treat      Hormone
steroids  training  training  underlying replacement
+saline   (12-24wk) (up to    disease    (hypogonadism)
irrigation          18 months) OD is     Anosmia —
Systemic  Vit A     observation irreversible permanent
steroids  nasal drops          │
FESS if   Alpha-    Counsel    Prodromal
indicated lipoic    re: safety PD screening
          acid               role
   │
   ▼
RESPONSE ASSESSMENT
(Repeat UPSIT / Sniffin' Sticks at 3 months)
   │
 ┌─┴─┐
YES   NO
 │     │
Continue Escalate / MRI / OERPs /
maintain Consider PRP / further
treatment specialist referral

---

12. COMPLICATIONS OF ANOSMIA

• Safety hazards: Inability to detect gas leaks, fire smoke, spoiled food
• Nutritional: Reduced appetite → malnutrition (especially elderly)
• Quality of life: Significant depression, reduced hedonic response, sexual dysfunction
• Marital/social: Loss of intimacy (olfaction important for pheromone-mediated social bonding)
• Occupational: Chefs, food/beverage industry, firemen, chemical workers
• Parosmia/Phantosmia during recovery phase — distressing
• In COVID-19: persistent OD associated with post-COVID syndrome (long COVID)

---

13. PROGNOSIS

---

14. SPECIAL TOPICS

14.1 Unilateral Anosmia — Clinical Significance

14.2 Foster Kennedy Syndrome

• Olfactory groove meningioma → ipsilateral anosmia + optic nerve atrophy + contralateral papilledema
• Important exam association (Stell & Maran's HNS)

14.3 Olfactory Neuroblastoma (Esthesioneuroblastoma)

• Arises from olfactory neuroepithelium
• Hyams grading (I–IV); Kadish staging (A–C)
• Presents with unilateral nasal obstruction + epistaxis + anosmia
• Treatment: surgery (craniofacial resection or endoscopic) + radiotherapy

14.4 Olfaction and COVID-19 — Landmark Observations

• Unlike CRS-related OD, COVID-19 OD shows no olfactory cleft mucosal thickening on CT/MRI
• SARS-CoV-2 infects ACE2/TMPRSS2-expressing sustentacular cells and horizontal basal cells, not ORNs directly
• Subsequent ORN death is secondary to loss of sustentacular cell support
• Anosmia has highest diagnostic value as symptomatic predictor of COVID-19 (strongest single symptom predictor)
• Prevalence: 15–96% depending on variant and measurement modality
• Omicron variant: lower rate of OD compared to Delta/original strain

---

15. RECENT ADVANCES (2020–2024)

---

16. SUMMARY TABLE — HIGH-YIELD FACTS FOR EXAMINATION

---

REFERENCES

1. Harrison's Principles of Internal Medicine, 21st Edition — pp. 1007, 1009, 1013 (Smell and Taste)
2. Scott Brown's Otorhinolaryngology, Head & Neck Surgery, 8th Edition — Olfaction chapter
3. Cummings Otolaryngology — Head and Neck Surgery, 7th Edition — Olfaction and Gustation
4. Stell & Maran's Textbook of Head and Neck Surgery and Oncology, 5th Edition
5. Dhingra P.L. — Diseases of Ear, Nose and Throat, 7th Edition
6. Hazarika P. — Textbook of ENT Head & Neck Surgery, 4th Edition
7. Zakir Hussain — A Short Textbook of ENT Diseases
8. International Consensus Statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR:RS) — pp. 6, 16
9. Hummel T et al. — "Effects of olfactory training in patients with olfactory loss" Laryngoscope 2009
10. Printza A, Constantinidis J — "COVID-19 associated olfactory dysfunction" — Rhinology 2021
11. Passali GC et al. — "PEA + luteolin in post-COVID anosmia" Pathogens 2021
12. Siu J et al. — "Budesonide nasal irrigation in CRS" Rhinology 2023
13. Braak H et al. — "Staging of Parkinson's disease" Cell Tissue Res 2004
14. Whitcroft KL, Hummel T — "Olfactory dysfunction in COVID-19" JAMA 2020

---